Orally disintegrating rimegepant increased freedom from pain and from most bothersome symptom at 2 h in acute migraine.

Pas encore traduit Pas encore traduit
Auteurs
Catégorie Primary study
JournalAnnals of Internal Medicine
Year 2019
Source Citation: Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394:737-45. 31311674 Clinical Impact Ratings: GIM/FP/GP: Neurology:
Epistemonikos ID: 887d0db769811f1c29741470e6d42aa0200abd6d
First added on: Apr 06, 2025